Overview

This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.

Eligibility

Inclusion Criteria:

• Diagnosis of ASCVD (coronary heart disease, peripheral arterial disease and/or cerebrovascular disease)
• High risk or very high risk for cardiovascular events (as per the 2019 ESC/EAS guidelines \[1\] for the management of dyslipidemias)
• Lipid levels:
  • High risk: LDL-C ≥70 mg/dl (or \> 1.8 mmol/L) or non-HDL-C ≥100 mg/dl
  • Very high risk: LDL-C ≥55 mg/dl (or \> 1.4 mmol/L) or non-HDL-C ≥85 mg/dl
• Male or Female
• 18 years or older
• Seen by a specialist who is prescribing advanced lipid lowering treatments (LLTs) (cardiologist, endocrinologist or any other relevant specialist)
• Currently taking maximum-tolerated statins
• Ability to participate in educational program (must be able to watch online videos)
• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

• Any surgical or medical condition, which in the opinion of the Investigator, may place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study.
• Unwillingness or inability (e.g., physical or cognitive) to comply with study procedures (including adherence to study visits).
• Participation in any other interventional study.
• Inability to travel to study sites for in-person clinic visits.
• Responsible physician clinical decision not to engage the identified patient.
• Refusal of the potential participant to sign the consent and be included in the model.

Other protocol-defined inclusion/exclusion criteria may apply